APAC Methadone Market

Asia Pacific Methadone Market Size & Growth (2022 to 2027):

As per the research report, the size of the Asia Pacific Methadone Market was valued at USD xx Million in 2022 and estimated to be growing at a CAGR of xx%, to reach USD xx Million by 2027 during the forecast period 2022 to 2027.

The market's growth is driven by the increase in the incidence of accidents, orthopedic diseases, and other chronic pain disorders. In addition, increasing disposable income, drug abuse, toxicity, and the rising geriatric population will drive the growth of the studied market. Methadone reduces withdrawal symptoms in people who use heroin or other drugs. Methadone is an excellent alternative to morphine sulfate and other opioid pain relievers due to its long half-life and low patient risk value. All of these factors support the burgeoning APAC methadone market.

Additionally, the market is strongly influenced by methadone maintenance therapy, which involves long-term use of the methadone formulation in opioid-dependent patients such as fentanyl, heroin, hashish, etc. In 2013, there were 2,475,500 registered drug addicts in China, including 1,326,500 heroin addicts, or 53.76% of the drug addict population. Some unofficial estimates reach 12.69 million drug addicts. In India, the use is reported in 2.18% of the total population, with heroin use highest at 1.148%, followed by pharmaceutical opioids with 0.968% and opium with 0.58%. Methadone is used in relieving severe pain in patients who take pain relievers 24 hours a day for a long time and cannot be treated with other drug variants. Methadone for pain management in developing APAC countries is projected to create lucrative opportunities for expanding the market shortly.

The increasing prevalence of emerging pain associated with the therapeutic and post-surgical treatment of cancer and other critical chronic diseases will significantly influence the market.

However, the emergence and legalization of cannabis as an alternative to methadone is hampering the market's growth. Moreover, due to some risks associated with the use of methadone in patients with severe asthma or breathing problems, you may restrict its use, which could slow down the market.

This research report on the APAC Methadone Market has been segmented and sub-segmented into the following categories:

By Application:

• Operation
• Detoxification
• Others

By Mode Of Administration:

• Injections
• Oral Medicine

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Australia methadone market dominated the APAC methadone market with a significant 35% share in 2020. It is due to the increasing incidence of drug addiction and a higher adoption rate of opioid pain relievers.

According to the United Nations Office on Drugs and Crime (UNODC), more than 47,500 people died of opioid overdoses, increasing the demand for methadone which acts as the opioid receptor. In addition, the increase in incidents of opioid abuse and the growing number of people habituated to heroin and other drugs and their treatment, which involves the short-term administration of methadone hydrochloride, only adds to the strong growth in the APAC market.

The Chinese methadone market will outperform all regions with the highest CAGR of 2.56% from 2022 to 2027. Because of population growth and increasing development in the healthcare sector, the increasing number of patients associated with pain and other chronic diseases will boost the market.

According to GLOBOCAN estimates, approximately 4,285,100 new cancer cases were diagnosed in China in 2019, of which 2,366,100 were men and 1,919,050 were women. The crude and age-standardized incidence rates for all cancers were 301.15 and 201.78 per 100,000, respectively.

KEY MARKET PLAYERS

The Top companies leading in the APAC Methadone Market profiled in the report are Diskets, Methadoes, Aurolife Pharma LLC, Macfarlan Smith, VistaPharm, Qinghai Pharm, CentralPharm, Mallinckrodt, and Roxane (Boehringer Ingelheim) among others.